ClinPGx Blog (Page 25)

Sign in Subscribe

More issues

CPIC Meeting at ASCPT on March 15, 2017

The Clinical Pharmacogenetics Implementation Consortium(CPIC®) Meeting will be held on March 15, 2017, in conjunction with the 2017 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) on March 15-18, 2017 (Washington, DC). The one-day symposium is organized by the Clinical Pharmacogenetics Implementation Consortium (CPIC®) (cpicpgx.

CPIC Seeks Feedback on Recommendation Strength and Gene/Drug Pair Level Definitions

CPIC is proposing changes to CPIC Guideline grades for strength of recommendation and for definitions of CPIC Levels of gene/drug pairs. Based on a review of other practices and challenges presented by some CPIC gene/drug pairs, it is recommended that the option "no recommendation" be added

Pharmacogenomics discussed in the Summer 2016 issue of Genome magazine

The current issue of Genome magazine includes the article "Determining a Drug Response", which provides a discussion of pharmacogenomics and contains interviews with multiple members of the Clinical Pharmacogenetics Implementation Consortium (CPIC), including Mark Dunnenberger (director of the pharmacogenomics program at NorthShore University HealthSystem), Stuart Scott (assistant professor

Standardized allele function and phenotype terms for clinical pharmacogenetic test results

In December 2014 and February 2015, we blogged about the CPIC term standardization project. CPIC (Clinical Pharmacogenetics Implementation Consortium) just published the results of this project in Genetics in Medicine. Consensus terms for allele function and phenotype were determined by starting with a broad list of terms currently used by

Improvements for Variant data in PharmGKB

PharmGKB is constantly improving the way we organize and annotate data in the field of pharmacogenomics. One of our recent improvements involves how we store and refer to Variants. Genetic variation is a very important part of what we do here at PharmGKB. That importance means we need a clear

Prediction of CYP2D6 phenotype from genotype across world populations

A. Gaedigk and S. Leeder together with PharmGKB published an article in Genetics in Medicine about the prediction of CYP2D6 phenotypes from genotype data across world populations (http://www.nature.com/gim/journal/vaop/ncurrent/full/gim201680a.html).In the supplemental materials of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines involving

Common variant found in populations of African descent linked with increased risk of venous thromboembolism

Roxana Daneshjou, along with co-authors Teri Klein and Russ Altman of PharmGKB, have published a paper describing a previously uncharacterized SNP in the Protein S (PROS1) gene that increases risk of venous thromboembolism (VTE). VTE is more common in African American populations than in populations of European descent, yet the

Wall Street Journal Discusses Predispositional Personal Genome Sequencing, PGx

A recent article by Laura Landro in the Wall Street Journal titled “Why Knowing Your Genetic Data Can Be a Tricky Proposition” discusses the benefits and complications of Predisposition Personal Genome Sequencing (PPGS) and the Personal Genome Sequencing Outcomes, or PeopleSeq consortium. PPGS is preemptive genome sequencing of apparently healthy

Congratulations to Dr. Rochelle Long in her new role at NIGMS

The PharmGKB team congratulates Dr. Rochelle Long, our program officer for the past 16 years, in her new role as Director of NIGMS Division of Pharmacology, Physiology, and Biological Chemistry. Dr. Long’s vision, leadership, dedication, friendship and support have been instrumental in elevating and maturing the field of pharmacogenomics.

Spring SNPits Summary

The Spring edition of UF Health Personalized Medicine Program's e-newsletter, SNPits is out now. This edition of SNPits summarizes and discusses publications in the American Journal of Health-System Pharmacy, Gastroenterology, and Genetics in Medicine. The first publication summary was of a retrospective study that analyzed the pharmacogenetic (PGx)